An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Comparison of each subject's synovial tissue markers
at baseline and after 4 months of treatment with abatacept
Bristol Myers Squibb
Study Director
Bristol-Myers Squibb
United Kingdom: Medicines and Healthcare Products Regulatory Agency
IM101-015
NCT00162201
December 2003
April 2005
Name | Location |
---|